Arylalkylamine-, β-carboline-, quinolizine- and azecine-derived compounds and their in vitro interaction with the ionotropic 5-HT₃ receptor: search for new lead structures

Abstract

Specific Serotonin receptor agonists and antagonists are marketed with respect to various diseases, most prominently severe emesis. To identify new chemical classes with affinity for the serotonin 5-HT₃ channel, several compounds were synthesized which can be structurally classified as arylalkylamines, azecines, quinolizines and β-carbolines. These were tested in three models: 1. direct effect on ileum (overall model for contracting or relaxant effect), 2. antiserotoninergic effects on rat ileum (crude serotonin model), 3. inhibitory effect on the 5-HT₃ receptor channel complex expressed in N1E-115 cells (serotonin-induced [¹⁴C]guanidinium influx (specific model)). Key findings and conclusion: Several azecine-type compounds exhibit 5-HT₃ receptor channel antagonistic properties at concentrations close to that of tropisetron (used as a positive control) and might serve as potential lead structures for the development of further 5-HT₃ channel receptor antagonists.

Key words

Azecine - β-Carboline - 5-HT3 receptor - Phenylalkylamine - Quinolizine

• References

• 1 Cash BD, Chey WD. Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation. Aliment Pharmacol Ther. 2005; 22: 1047-60
• 2 Mössner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun. 1998; 12: 249-71
• 3 Surgand JS, Rodrigo J, Rognan D. A chemogenomic analysis of the transmembrane binding cavity of human G-pro-tein-coupled receptors. Proteins. 2006; 62: 509-38
• 4 Costall B, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ. Zacopride: anxiolytic profile in rodent and primate models of anxiety. J Pharm Pharmacol. 1988; 40: 302-5
• 5 Smith WT, Londborg PD, Blomgren SL, Tollefson CD, Sayler ME. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999; 19: 125-31
• 6 Young R, Johnson DN. Anxiolytic-like activity of R(+)- and S(-)-zacopride in mice. Eur J Pharmacol. 1991; 201: 151-55
• 7 Lodge NJ, Li YW. Ion channels as potential targets for the treatment of depression. Curr Opin Drug Discov Devel. 2008; 11: 633-41
• 8 Buhot MC, Mallert G. Segul. Serotonin receptors and cognitive behaviour-an update. IDrugs. 1999; 2: 426-37
• 9 Sirota P, Mosheva T, Shabtay H, Giladi N, Korczyn AD. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiatry. 2000; 157: 287-9
• 10 Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res. 2006; 88: 102-10
• 11 Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res. 1994; 18: 879-85
• 12 McKinzie DL, McBride WJ, Murphy JM, Lumeng L, Li TK. Effects of MDL 72222, a serotonin3 antagonist, on operant responding for ethanol by alcohol-preferring P rats. Alcohol Clin Exp Res. 2000; 24: 1500-4
• 13 Kankaanpaa A, Meririnne E, Seppala T. 5-HT3 receptor antagonist MDL 72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat. Psychopharmacology (Berl). 2002; 159: 341-50
• 14 Kos T, Popik P, Pietraszek M, Schafer D, Danysz W, Dravolina O et al Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice. Eur Neuropsychopharmacol. 2006; 16: 297-10
• 15 Yoo JH, Nam YS, Lee SY, Jang CG. Dopamine neurotransmission is involved in the attenuating effects of 5-HT3 receptor antagonist MDL 72222 on acute methampheta-mine-induced locomotor hyperactivity in mice. Synapse. 2008; 62: 8-13
• 16 Fontana DJ, Daniels SE, Eglen RM, Wong EH. Stereoselective effects of (R)- and (S)-zacopride on cognitive performance in a spatial navigation task in rats. Neuropharmacology. 1996; 35: 321-327
• 17 Fontana DJ, Daniels SE, Henderson C, Eglen RM, Wong EH. Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacology (Berl). 1995; 120: 409-17
• 18 Bönisch H, Barann M, Graupner J, Göthert M. Characterization of 5-HT3 receptors of N1E-115 neuroblastoma cells by use of the influx of the organic cation [14C]-guanidi-nium. Br J Pharmacol. 1993; 108: 436-42
• 19 Abdel-Aziz H, Nahrstedt A, Petereit F, Windeck T, Ploch M, Verspohl EJ. 5-HT3 receptor blocking activity of arylal-kanes isolated from the rhizome of Zingiber officinale. Planta Med. 2005; 71: 609-16
• 20 Glennon RA, Raghupathi R, Bartyzel P, Teitler M, Leonhardt S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J Med Chem. 1992; 35: 734-40
• 21 Glennon RA, Gessner PK. Serotonin receptor binding affinities of tryptamine analogues. J Med Chem. 1979; 22: 428-32
• 22 Ho BT, Li KC, Walker KE, Tansey LW, Kralik PM, Mclsaac WM. Inhibitors of monoamine oxidase. VI. Effects of substitution on inhibitory activity of 6 (or 8)-substituted beta-carbolines. J Pharm Sc. 1970; 59: 1445-8
• 23 Schott Y, Decker M, Rommelspacher H, Lehmann J. 6-Hy-droxy- and 6-methoxy-beta-carbolines as acetyl- and bu-tyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006; 16: 5840-3
• 24 Fourneau JP, Delestrange Y. Dérives de la N-phényléthylè-nediamine. Bull Soc Chim France. 1947; 14: 827-38 French
• 25 Schmutz J, Kunzle F. Piperazino-l’,2–l,2-Benzimidazole. Helv Chim Acta. 1956; 39: 1144-56
• 26 HoefgenBDecker M, Mohr P, Schramm AM, Rostom SA, ElSubbagh H et al Dopamine/serotonin receptor ligands. 10: SAR studies on azecine-type dopamine receptor ligands by functional screening at human cloned Dl, D2L, and D5 receptors with a microplate reader based calcium assay lead to a novel potent D1/D5 selective antagonist. J Med Chem. 2006; 49: 760-9
• 27 Mohr P, Decker M, Enzensperger C, Lehmann J. Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first pi-comolar D5-selective dopamine-receptor antagonist. J Med Chem. 2006; 49: 2110-6
• 28 Enzensperger C, Gornemann T, Pertz HH, Lehmann J. Dopamine/serotonin receptor ligands. Part 17: A cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D(l) and D(2) receptors. Bioorg Med Chem Lett. 2008; 18 (13) 3809-13
• 29 Enzensperger C, Kilian S, Ackermann M, Koch A, Kelch K, Lehmann J. Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists. Bioorg Med Chem Lett. 2007; 17: 1399-402
• 30 Wernicke C, Schott Y, Enzensperger C, Schulze G, Lehmann J. Cytotoxicity of beta-carbolines in dopamine transporter expressing cells: structure-activity relationships. Biochem Pharmacol. 2007; 74: 1065-77
• 31 Abdel-Aziz H, Windeck T, Ploch M, Verspohl EJ. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol. 2006; 530: 136-43
• 32 Lopez-RodriguezMLMorcillo MJ, Benhamu B, Rosado ML. Comparative receptor mapping of serotoninergic 5-HT3 and 5-HT4 binding sites. J Comput Aided Mol Des. 1997; 11: 589-99
• 33 Heinzelmann RV, Anthony WC, Lyttle DA, Szmuszkovicz J. The synthesis of α-methyltryptophans and α-alkyltrypta-mines. J Org Chem. 1960; 25: 1548-58
• 34 Enzensperger C, Lehmann J. Dopamine/serotonin receptor ligands. 13: Homologization of a benzindoloazecine-type dopamine receptor antagonist modulates the affinities for dopamine D(l)-D(5) receptors. J Med Chem. 2006; 49: 6408-11
• 35 Enzensperger C, Müller FK, Schmalwasser B, Wiecha P, Traber H, Lehmann J. Dopamine/serotonin receptor ligands. 16.(1) Expanding dibenz[d,g]azecines to 11- and 12-membered homologues. Interaction with dopamine D(l)-D(5) receptors. J Med Chem. 2007; 50: 4528-33